Mark Cuban Cost Plus Drug Company rolls out digital pharmacy

The Mark Cuban Value Plus Drug Firm is leaping into the web pharmacy sector, launching a brand new digital market. The corporate pitches the digital pharmacy as a manner to assist shoppers discover medicines for much less cash. 

In November, the corporate unveiled its pharmacy profit supervisor (PBM) operation, which the corporate says lets them lower out the “middlemen” and worth markups of their on-line pharmacy. 

In response to the corporate’s web site, the pharmacy will provide medicines that target diabetes, coronary heart well being, gastrointestinal points, psychological well being, most cancers, antibiotics and different areas. 


In response to Kaiser Family Foundation analysis, 83% of adults say that the price of prescribed drugs is unreasonable. Moreover, 35% of survey respondents with a family revenue of $40,000 or much less reported having issue affording their prescribed drugs. 

The MCCPDC is pitching its new system as a strategy to mitigate drug prices by working each as a PBM and retailer. 

“There are quite a few unhealthy actors within the pharmaceutical provide chain stopping sufferers from getting inexpensive medicines,” Alex Oshmyansky, CEO of the MCCPDC, mentioned in an announcement. “The one manner to make sure inexpensive costs get via is to vertically combine.”


There are a number of on-line drug retailers as we speak. Massive tech has additionally demonstrated curiosity within the sector. In 2018, Amazon entered the area after buying digital pharmacy PillPack for just under $1 billion. Amazon later built-in PillPack and rolled out Amazon Pharmacy, a digital store that lets prospects order and handle their prescription medicines on-line and get them delivered to their properties.

Buyers have taken discover of digital pharmacies, pouring a whole bunch of tens of millions of {dollars} into the area. In April, on-line pharmacy Capsule completed a $300 million funding round, which introduced the corporate’s complete valuation to $1 billion.

In 2020, Alto, a digital pharmacy and drug supply firm, closed a $250 million Sequence D funding spherical led by SoftBank’s Imaginative and prescient Fund 2. 


Leave a Reply